Moderna's stock surged over 125% in one week, driven by positive interim results from its Phase 3 trial of a personalized mRNA cancer vaccine for high-risk melanoma patients. The trial, conducted with partner Merck, showed success without new safety concerns, pushing Moderna's stock to a 52-week high. Despite this, Wall Street analysts remain cautious, with mixed ratings and an average 12-month price target suggesting potential declines. The stock's inclusion in former President Trump's portfolio may support continued investor interest amid the breakthrough news.
Moderna and Merck announced successful Phase 3 trial results for their personalized mRNA melanoma vaccine combined with Keytruda, showing significant improvement in recurrence-free and distant metastasis-free survival. This marks the first positive l...
Tempus AI agreed to acquire Personalis for $1.5 billion in a stock deal, gaining access to Personalis's ultrasensitive cancer DNA detection test, NeXT Personal. This technology supports a personalized mRNA cancer vaccine by Moderna and Merck, which r...
Moderna's stock jumped 93% following the announcement that its Phase 3 melanoma trial, conducted with Merck, met its primary endpoint by significantly improving recurrence-free survival when combined with Merck's Keytruda. This marks the first positi...
Moderna and Merck reported positive Phase 3 trial results for their personalized mRNA-based cancer vaccine combined with Keytruda, showing significant improvement in recurrence-free survival for melanoma patients. This marks the first successful Phas...
Merck and Moderna announced positive initial results from their first late-stage trial of an experimental personalized cancer vaccine combined with Merck's immunotherapy Keytruda. The phase three trial involving over 1,100 melanoma patients showed th...
